Seiichiro Hojo

597 total citations
26 papers, 486 citations indexed

About

Seiichiro Hojo is a scholar working on Rheumatology, Genetics and Oncology. According to data from OpenAlex, Seiichiro Hojo has authored 26 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 7 papers in Genetics and 7 papers in Oncology. Recurrent topics in Seiichiro Hojo's work include Systemic Lupus Erythematosus Research (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Seiichiro Hojo is often cited by papers focused on Systemic Lupus Erythematosus Research (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Seiichiro Hojo collaborates with scholars based in Japan, United States and Russia. Seiichiro Hojo's co-authors include Yasumi Kitahara, Hideto Akama, Masutaka Furue, Nobukazu Hayashi, Seiichi Hayato, Kenji Ikeda, Toshiyuki Tamai, Takuya Suzuki, Takuji Okusaka and Hiromitsu Kumada and has published in prestigious journals such as Annals of the Rheumatic Diseases, Human Pathology and Cancer Science.

In The Last Decade

Seiichiro Hojo

24 papers receiving 481 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seiichiro Hojo Japan 13 150 130 118 99 99 26 486
Sharada L. Truter United States 10 33 0.2× 32 0.2× 123 1.0× 82 0.8× 32 0.3× 23 725
Daniele Cattaneo Italy 16 25 0.2× 196 1.5× 25 0.2× 50 0.5× 45 0.5× 65 624
Chul‐Soo Cho South Korea 12 30 0.2× 203 1.6× 28 0.2× 87 0.9× 227 2.3× 19 602
Zsuzsa Sándor Hungary 10 21 0.1× 194 1.5× 17 0.1× 67 0.7× 105 1.1× 15 456
Justyna Chwiećko Poland 13 14 0.1× 287 2.2× 53 0.4× 93 0.9× 125 1.3× 27 533
Florian Puls United Kingdom 19 25 0.2× 375 2.9× 18 0.2× 257 2.6× 11 0.1× 44 968
Henrietta Dér Hungary 9 26 0.2× 234 1.8× 19 0.2× 21 0.2× 228 2.3× 12 466
Sonia Pezet France 10 53 0.4× 50 0.4× 6 0.1× 28 0.3× 103 1.0× 13 456
Annalisa La Cesa Italy 14 28 0.2× 70 0.5× 7 0.1× 459 4.6× 24 0.2× 24 657

Countries citing papers authored by Seiichiro Hojo

Since Specialization
Citations

This map shows the geographic impact of Seiichiro Hojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiichiro Hojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiichiro Hojo more than expected).

Fields of papers citing papers by Seiichiro Hojo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiichiro Hojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiichiro Hojo. The network helps show where Seiichiro Hojo may publish in the future.

Co-authorship network of co-authors of Seiichiro Hojo

This figure shows the co-authorship network connecting the top 25 collaborators of Seiichiro Hojo. A scholar is included among the top collaborators of Seiichiro Hojo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seiichiro Hojo. Seiichiro Hojo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harada, Kenichi, Yuko Kakuda, Atsushi Tanaka, et al.. (2025). Histological characteristics of primary biliary cholangitis in patients with incomplete responses to ursodeoxycholic acid. Human Pathology. 166. 105957–105957.
2.
Tanaka, Atsushi, Masanori Abe, Tadashi Namisaki, et al.. (2025). A placebo-controlled Phase 2 trial of E6011, anti-human fractalkine monoclonal antibody, in primary biliary cholangitis. Journal of Translational Autoimmunity. 10. 100283–100283. 3 indexed citations
3.
Izutsu, Koji, Kiyoshi Ando, Momoko Nishikori, et al.. (2024). Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. International Journal of Hematology. 120(5). 621–630. 5 indexed citations
4.
Tanaka, Yoshiya, Tsutomu Takeuchi, Hisashi Yamanaka, et al.. (2023). Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate. Modern Rheumatology. 34(1). 37–44. 8 indexed citations
5.
Tanaka, Yoshiya, Tsutomu Takeuchi, Hisashi Yamanaka, et al.. (2023). Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. Modern Rheumatology. 34(1). 45–49. 2 indexed citations
6.
Nakai, Kenya, Yasumi Kitahara, Seiichiro Hojo, et al.. (2022). First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers. Clinical Pharmacology in Drug Development. 12(4). 363–375. 15 indexed citations
7.
Izutsu, Koji, Kiyoshi Ando, Momoko Nishikori, et al.. (2021). Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Science. 112(9). 3627–3635. 47 indexed citations
8.
Tanaka, Yoshiya, Tsutomu Takeuchi, Hisashi Yamanaka, et al.. (2021). A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. Modern Rheumatology. 31(4). 783–789. 19 indexed citations
9.
10.
11.
Tanaka, Yoshiya, Tsutomu Takeuchi, Hisashi Yamanaka, et al.. (2019). SAT0126 A PHASE 2 STUDY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO BIOLOGICS. Annals of the Rheumatic Diseases. 78. 1131–1132. 4 indexed citations
12.
Kitahara, Yasumi, et al.. (2018). Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis. Journal of Dermatological Treatment. 30(5). 466–470. 4 indexed citations
13.
Kinoshita, Yoshikazu, Mototsugu Kato, Mitsuhiro Fujishiro, et al.. (2017). Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. Journal of Gastroenterology. 53(7). 834–844. 19 indexed citations
14.
Tanaka, Yoshiya, Tsutomu Takeuchi, Hisanori Umehara, et al.. (2017). Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Modern Rheumatology. 28(1). 58–65. 50 indexed citations
15.
Tanaka, Yoshiya, Takumi Takeuchi, Hisanori Umehara, et al.. (2017). SAT0187 Safety, pharmacokinetics and efficacy of e6011, an anti-fractalkine monoclonal antibody, in a first-in-patient phase 1/2 study in rheumatoid arthritis; addtional data of 400 mg cohort. Annals of the Rheumatic Diseases. 76. 842–842. 2 indexed citations
16.
Tamai, Toshiyuki, Seiichi Hayato, Seiichiro Hojo, et al.. (2017). Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses. The Journal of Clinical Pharmacology. 57(9). 1138–1147. 81 indexed citations
17.
Tanaka, Yoshiya, Tsutomu Takeuchi, Hisanori Umehara, et al.. (2016). FRI0236 Safety, Pharmacokinetics and Efficacy of E6011, An Anti-Fractalkine Monoclonal Antibody, in A First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 75. 519–519. 2 indexed citations
18.
Furue, Masutaka, Yasumi Kitahara, Hideto Akama, et al.. (2014). Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in J apanese adult patients with atopic dermatitis: Results of a randomized, vehicle‐controlled, multicenter clinical trial. The Journal of Dermatology. 41(7). 577–585. 68 indexed citations
19.
Hayato, Seiichi, Setsuo Hasegawa, Seiichiro Hojo, et al.. (2011). Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. European Journal of Clinical Pharmacology. 68(5). 579–588. 12 indexed citations
20.
Tanaka, Takanori, Seiichiro Hojo, Masahiro Yamashita, Hiroyuki Doi, & Kazuhiro Hoshi. (2004). Pharmacodynamics of Three Different Routes of Administration of Natural Type Interferon-.BETA. in Healthy Volunteers. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 35(4). 181–188.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sharada L. Truter Breakdown of academic impact, for papers by Daniele Cattaneo Breakdown of academic impact, for papers by Chul‐Soo Cho Breakdown of academic impact, for papers by Zsuzsa Sándor Breakdown of academic impact, for papers by Justyna Chwiećko Breakdown of academic impact, for papers by Florian Puls Breakdown of academic impact, for papers by Henrietta Dér Breakdown of academic impact, for papers by Sonia Pezet Breakdown of academic impact, for papers by Annalisa La Cesa
Rankless by CCL
2026